(201) 392 3100
Bio
Dr. Tsenovoy is the Chief of Cardiology at Hudson Regional Hospital. He attended Moscow Sechenov Medical Academy and continued his medical education in the United States at New York Medical College. Here, Dr. Tsenovoy received residency training in internal medicine and completed a fellowship program in cardiovascular disease.
Patients visiting Dr. Tsenovoy can receive a full range of medical services. He provides general cardiology consultations, as well as treatment for specific illnesses and issues. In addition to his practice, Dr. Tsenovoy has published extensively and participated in clinical research programs at Harvard Medical School and New York Medical College.
Education
Westchester Medical Center - Fellowship
Valhalla, NY
July, 2009 - June, 2012
Fellow-Cardiovascular Fellowship
Westchester Medical Center - Residency
Valhalla, NY
July, 2007 - June, 2009
Internal Medicine Resident PGY-2, 3
New York Medical College, Westchester Medical Center, Department of Pharmacology - Clinical Research
Valhalla, NY
July, 2006 - June, 2007
Advanced Cardiovascular Clinical Research
Westchester Medical Center - Residency
Valhalla, NY
July, 2005 - June, 2006
Internal Medicine Resident PGY-1
New York Medical College, Westchester Medical Center, Department of Pharmacology - Clinical Research
Valhalla, NY
June, 2003 - June, 2005
Clinical Research
Clinical Research with Dr. Nader Abraham. Research on the role of endothelial stem cell in hypertension, diabetes, and renal failure.
Beth Israel Deaconess Medical Center - Fellowship
Boston, MA
2001 - 2003
Gastroenterology research fellowship
Moscow Sechenov Medical Academy - Medical Education
Moscow, Russia
1990 - 1996
MD
Awards/Honors
New York Medical College Department of Medicine: The Richard D. Levere Excellence in Teaching Award, July-September, 2007
Publications
The effects of free radicals caused by obesity in ischemic heart.
In editorial review
2011
Other contributors include Abraham NG, Peterson SJ, Aranow WS, and McClung JA.
Usefulness of clopidogrel to protect against diabetes-induced vascular damage.
American Journal of Cardiology. (Online)
2010
Other contributors include McClung JA, Kruger AL, Ferraris A, Vanella L, Weiss MB, and Abraham NG.
Heme Osygenase Function in the Cardiovascular System.
American Journal of Cardiology.
2008
Other contributors include Abraham NG and Peterson SJ.
Existence of a HO-1 Adiponectin Axis; Crucial for Vascular Protection in Type 1 Diabetes.
American Journal of Physiology-Renal.
2008
Other contributors include Abraham NG, Li M, Kim DH, Kawakami T, Rodella LF, Rezzani R, Peterson SJ, Drummond G, and Falck JR.
Heme Oxygenase-1 in Diabetes and Metabolic Syndrome.
Current Pharmaceutical Design.
2008
Other contributors include Abraham NG and Drummond G.
The Essential Role of the L4F-Adiponectin Regulatory Axis: Leading to Improvements in the Metabolic Profile of Diabetes Mellitus.
American Society of Physiology
2008
Other contributors include Burgess A, Peterson SJ, Li M, Kim DH, and Abraham NG.
Patients with infective endocarditis and increased cardiac troponin I levels have a higer incidence of in-hospital mortality and valve replacement than those with normal cardiac troponin I levels.
Cardiology. (Online)
2009
Other contributors include Aronow WS, Joseph J and Kopacz MS.
Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insuline sensitivity and glucose tolerance.
Diabetes
2008
Other contributors include Li M, Kim DH, Peterson SJ, Rezzani R, Rodella LF, Aronow WS, Ikehara S, and Abraham NG.
Heme oxygenase-mediated increases in adiponectin decrease fat content and inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 in Zucker rats and reduce adipogenesis in human mesenchymal stem cells.
Journal of Pharmacology and Experimental Therapeutics. (Online)
2008
Other contributors include Kim DH, Burgess AP, Li M, Addabbo F, McClung JA, Puri N, and Abraham NG.
Heme oxygenase: a target gene for anti-diabetic and obesity.
Current Pharmaceutical Design. (Online)
2008
Other contributors include Abraham NG, McClung J, and Drummond GS.
Heme Oxygenase Expression in Diabetes and in Renal Diseases: Mechanisms of Cytoprotection.
Drug Discovery Today: Disease Mechanisms.
2007
Other contributors include Abraham NG, and Goodman AI.
Apolipoprotein A-1 Mimetic Peptide, L-4F, Treatment Ameliorate Diabetes and High Fat - Induced Resistance Through Inhibition of Interleukin 1B, Increase in Adiponectin in Obese Mice.
Journal of Lipid Research.
2007
Other contributors include Peterson SJ, Rezzani R, Li M, Kim DH, Asiprino D, and Abraham NG.
Heme Oxygenase-1 (HO-1) preserves renal morphology and Acute Tubular Necrosis independent of hematopoetic progenitor-enriched CD34+ cells.
Journal of the American Society of Nephrology
2005
Other contributors include Peterson SJ, Goodman AI, and Abraham NG.
Regulation of iNOS and eNOS mediated by Heme Oxygenase-1 (HO-1) provides protection against Acute Tubular Necrosis.
Journal of the American Society of Nephrology
2005
Other contributors include Goodman AI, Van Drische, Peterson SJ, and Abraham NG.
